在治疗化物中β-的机制:网络药理学,分子对接和实验验证
Pingping Huo1, Zhouna Li2, Shan Jin1
1Keloid Research Center, Department of Dermatology, Yanbian University Hospital, Yanji, Jilin 133000, P.R. China.
Molecular medicine reports
|February 21, 2025
概括
贝塔-固醇 (SIT) 通过抑制细胞增殖和迁移,有效地治疗 keloids. 这项研究揭示了SIT调节PTEN/PI3K/AKT通路,为 keloid 痕提供了一个新的治疗策略.
科学领域:
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 状体是异常的痕,其治疗机制尚不清楚.
- 贝塔-固醇 (SIT) 显示出潜在的抗炎和抗纤维性作用.
- 了解SIT的 keloid 处理机制至关重要.
研究的目的:
- 阐明SIT对质体的治疗效果和机制.
- 为了研究SIT对状细胞行为和信号通路的影响.
- 在临床前的 keloid 模型中评估 SIT 的疗效.
主要方法:
- 生物信息学分析确定了关键目标.
- 分子对接评估了SIT的结合亲和力.
- 在体外测试评估了细胞活力,增殖,迁移和入侵.
- 西方斑点分析了EMT和PI3K/AKT通路中的蛋白质表达.
- 在体内研究中,使用了裸体老鼠的 keloid 模型.
主要成果:
- 在SIT的研究中,SIT对PTEN有强烈的结合.
- SIT 抑制了 keloid 细胞的活力,迁移和入侵.
- 在SIT下调的p-PI3K,p-AKT,Vimentin和Snail.
- 在SIT上调节了Zonula Occludens-1和E-cadherin.
- 在体内,SIT抑制了 keloid 的生长,并增加了 PTEN 的表达.
结论:
- SIT 抑制了 keloid 的增殖,迁移和入侵.
- 通过调节 PTEN/PI3K/AKT 信号通路,SIT 发挥其作用.
- 作为一种新的治疗药物,SIT显示出它对 keloid 治疗具有前途意义.
相关概念视频
Allosteric Regulation
57.5K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
57.5K
Structure-Activity Relationships and Drug Design
484
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
484
Targets for Drug Action: Overview
6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
Ligand Binding and Linkage
4.7K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.7K


